Inspire Medical (INSP) Crashes Over 32%, “Inspire V” Launch Failure, Hagens Berman Urges Investors with Losses to Contact Firm by Jan. 5

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which only took effect on July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a demand issue for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the concealment of critical points regarding the Medicare claims software failure and the inventory glut of the prior device as part of their investigation [5]. - Whistleblowers with non-public information about Inspire are encouraged to come forward, as they may be eligible for rewards under the SEC Whistleblower program [6].